A systematic review in 2617 NAFLD individuals with and without T2DM reported that few antidiabetic medications improve liver enzymes, but only glitazones and glucagon-like peptide 1 receptor (GLP-1) agonists, liraglutide and semaglutide, appear to improve NAFLD histology. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.